| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 194 | 2025 | 2390 | 21.910 |
Why?
|
| Research Design | 44 | 2026 | 722 | 12.540 |
Why?
|
| Energy Intake | 55 | 2025 | 501 | 8.550 |
Why?
|
| Body Mass Index | 114 | 2025 | 1695 | 8.220 |
Why?
|
| Weight Loss | 53 | 2025 | 529 | 8.120 |
Why?
|
| Longevity | 41 | 2026 | 176 | 7.810 |
Why?
|
| Body Weight | 64 | 2025 | 990 | 7.600 |
Why?
|
| Randomized Controlled Trials as Topic | 48 | 2026 | 1255 | 7.000 |
Why?
|
| Eating | 24 | 2025 | 382 | 5.240 |
Why?
|
| Data Interpretation, Statistical | 26 | 2024 | 227 | 4.920 |
Why?
|
| Body Composition | 56 | 2025 | 550 | 4.580 |
Why?
|
| Feeding Behavior | 23 | 2025 | 724 | 4.510 |
Why?
|
| Nutritional Sciences | 12 | 2021 | 66 | 4.480 |
Why?
|
| Pediatric Obesity | 15 | 2020 | 416 | 3.960 |
Why?
|
| Overweight | 19 | 2025 | 377 | 3.870 |
Why?
|
| Bias | 18 | 2025 | 144 | 3.710 |
Why?
|
| Diet | 32 | 2025 | 1121 | 3.680 |
Why?
|
| Humans | 438 | 2026 | 131604 | 3.670 |
Why?
|
| Exercise | 18 | 2024 | 866 | 3.540 |
Why?
|
| Energy Metabolism | 40 | 2025 | 785 | 3.490 |
Why?
|
| Caloric Restriction | 25 | 2025 | 106 | 3.430 |
Why?
|
| Models, Statistical | 33 | 2026 | 492 | 3.120 |
Why?
|
| Blood Glucose | 20 | 2026 | 1104 | 3.000 |
Why?
|
| Aging | 31 | 2026 | 1264 | 2.930 |
Why?
|
| Weight Reduction Programs | 6 | 2025 | 58 | 2.930 |
Why?
|
| Schools | 9 | 2023 | 240 | 2.930 |
Why?
|
| Models, Genetic | 25 | 2020 | 752 | 2.780 |
Why?
|
| Weight Gain | 24 | 2024 | 384 | 2.740 |
Why?
|
| Public Health | 8 | 2023 | 276 | 2.710 |
Why?
|
| Random Allocation | 14 | 2024 | 423 | 2.660 |
Why?
|
| Adipose Tissue | 32 | 2024 | 495 | 2.450 |
Why?
|
| Diet, Reducing | 12 | 2021 | 90 | 2.420 |
Why?
|
| Biomedical Research | 11 | 2026 | 556 | 2.270 |
Why?
|
| Female | 244 | 2026 | 71145 | 2.120 |
Why?
|
| Male | 241 | 2026 | 65228 | 2.120 |
Why?
|
| Dietary Supplements | 12 | 2024 | 453 | 2.080 |
Why?
|
| Social Class | 8 | 2019 | 211 | 2.050 |
Why?
|
| Statistics as Topic | 8 | 2018 | 244 | 2.050 |
Why?
|
| Breakfast | 4 | 2023 | 11 | 2.040 |
Why?
|
| Cluster Analysis | 15 | 2026 | 418 | 1.970 |
Why?
|
| Computer Simulation | 21 | 2025 | 685 | 1.940 |
Why?
|
| Breast Feeding | 8 | 2025 | 234 | 1.840 |
Why?
|
| Health Promotion | 7 | 2020 | 407 | 1.830 |
Why?
|
| Periodicals as Topic | 9 | 2025 | 180 | 1.810 |
Why?
|
| Adult | 138 | 2026 | 31702 | 1.790 |
Why?
|
| Environment | 9 | 2018 | 149 | 1.750 |
Why?
|
| Cardiovascular Diseases | 16 | 2023 | 2082 | 1.740 |
Why?
|
| Obesity, Morbid | 8 | 2018 | 233 | 1.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2026 | 1413 | 1.730 |
Why?
|
| Motor Activity | 13 | 2018 | 507 | 1.680 |
Why?
|
| Gardening | 2 | 2025 | 18 | 1.680 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2010 | 1008 | 1.680 |
Why?
|
| Anti-Obesity Agents | 11 | 2023 | 46 | 1.650 |
Why?
|
| Choice Behavior | 5 | 2023 | 132 | 1.640 |
Why?
|
| Beverages | 7 | 2019 | 100 | 1.600 |
Why?
|
| Vegetables | 5 | 2023 | 271 | 1.580 |
Why?
|
| Dietary Fats | 12 | 2020 | 276 | 1.570 |
Why?
|
| Animals | 132 | 2026 | 34371 | 1.570 |
Why?
|
| Life Expectancy | 6 | 2025 | 63 | 1.570 |
Why?
|
| Reproduction | 8 | 2024 | 215 | 1.560 |
Why?
|
| Reproducibility of Results | 29 | 2025 | 2986 | 1.550 |
Why?
|
| Quantitative Trait Loci | 15 | 2012 | 307 | 1.480 |
Why?
|
| Nutritional Status | 6 | 2023 | 302 | 1.430 |
Why?
|
| Causality | 7 | 2023 | 91 | 1.390 |
Why?
|
| Food | 9 | 2018 | 125 | 1.330 |
Why?
|
| Spinal Cord Injuries | 5 | 2022 | 278 | 1.320 |
Why?
|
| Research | 5 | 2024 | 266 | 1.320 |
Why?
|
| Motivation | 5 | 2025 | 334 | 1.250 |
Why?
|
| Regression Analysis | 27 | 2024 | 773 | 1.240 |
Why?
|
| Dietary Carbohydrates | 6 | 2022 | 108 | 1.240 |
Why?
|
| Malus | 2 | 2019 | 12 | 1.240 |
Why?
|
| Fruit | 6 | 2020 | 234 | 1.230 |
Why?
|
| Observational Studies as Topic | 6 | 2024 | 99 | 1.220 |
Why?
|
| Obesity, Abdominal | 2 | 2020 | 41 | 1.220 |
Why?
|
| Scientific Experimental Error | 2 | 2020 | 2 | 1.200 |
Why?
|
| Dietary Proteins | 5 | 2025 | 216 | 1.190 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2025 | 67 | 1.170 |
Why?
|
| Models, Biological | 14 | 2024 | 1392 | 1.160 |
Why?
|
| Waist Circumference | 6 | 2016 | 95 | 1.160 |
Why?
|
| Sleep | 3 | 2025 | 373 | 1.130 |
Why?
|
| Exercise Therapy | 5 | 2023 | 175 | 1.130 |
Why?
|
| Retraction of Publication as Topic | 2 | 2020 | 4 | 1.130 |
Why?
|
| Dementia | 2 | 2023 | 433 | 1.110 |
Why?
|
| Science | 4 | 2024 | 36 | 1.110 |
Why?
|
| Mice | 63 | 2026 | 18486 | 1.100 |
Why?
|
| Cellular Senescence | 8 | 2026 | 221 | 1.100 |
Why?
|
| Mice, Inbred C57BL | 32 | 2024 | 4769 | 1.090 |
Why?
|
| Metformin | 3 | 2019 | 168 | 1.090 |
Why?
|
| Editorial Policies | 2 | 2020 | 49 | 1.070 |
Why?
|
| Diet, Carbohydrate-Restricted | 5 | 2024 | 27 | 1.070 |
Why?
|
| Middle Aged | 95 | 2026 | 28883 | 1.060 |
Why?
|
| Sweetening Agents | 4 | 2012 | 37 | 1.060 |
Why?
|
| Behavior Therapy | 4 | 2025 | 272 | 1.050 |
Why?
|
| Selection, Genetic | 7 | 2018 | 157 | 1.050 |
Why?
|
| Sample Size | 6 | 2022 | 86 | 1.030 |
Why?
|
| Health Behavior | 8 | 2021 | 390 | 1.030 |
Why?
|
| Chromosome Mapping | 18 | 2010 | 1069 | 1.030 |
Why?
|
| Peer Review, Research | 4 | 2016 | 45 | 1.020 |
Why?
|
| Lipid Metabolism | 3 | 2026 | 371 | 1.010 |
Why?
|
| Publishing | 8 | 2025 | 105 | 1.000 |
Why?
|
| Milk, Human | 3 | 2025 | 318 | 1.000 |
Why?
|
| Appetite Regulation | 6 | 2014 | 44 | 1.000 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 10 | 2019 | 77 | 0.980 |
Why?
|
| Housing, Animal | 1 | 2026 | 19 | 0.980 |
Why?
|
| Bariatric Surgery | 2 | 2018 | 155 | 0.980 |
Why?
|
| Aged | 62 | 2026 | 21255 | 0.970 |
Why?
|
| Anthropometry | 11 | 2020 | 190 | 0.970 |
Why?
|
| Flax | 1 | 2026 | 4 | 0.960 |
Why?
|
| Research Report | 3 | 2024 | 71 | 0.960 |
Why?
|
| Mortality | 7 | 2024 | 261 | 0.960 |
Why?
|
| Cholesterol | 12 | 2023 | 541 | 0.940 |
Why?
|
| Ghrelin | 5 | 2023 | 58 | 0.940 |
Why?
|
| Adolescent | 51 | 2026 | 20931 | 0.940 |
Why?
|
| Neuralgia | 3 | 2022 | 51 | 0.930 |
Why?
|
| Seeds | 1 | 2026 | 42 | 0.930 |
Why?
|
| Genetic Linkage | 8 | 2015 | 472 | 0.930 |
Why?
|
| Glucagon-Like Peptides | 1 | 2025 | 39 | 0.930 |
Why?
|
| Diet, High-Protein | 1 | 2025 | 5 | 0.920 |
Why?
|
| Waist-Hip Ratio | 5 | 2010 | 54 | 0.910 |
Why?
|
| Simian Immunodeficiency Virus | 13 | 2019 | 100 | 0.900 |
Why?
|
| Linear Models | 10 | 2022 | 695 | 0.890 |
Why?
|
| Child | 45 | 2026 | 26250 | 0.880 |
Why?
|
| School Health Services | 3 | 2015 | 103 | 0.880 |
Why?
|
| Enteral Nutrition | 2 | 2018 | 281 | 0.880 |
Why?
|
| Statistics, Nonparametric | 5 | 2021 | 432 | 0.880 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 475 | 0.870 |
Why?
|
| Health Policy | 4 | 2017 | 227 | 0.870 |
Why?
|
| Lactation | 3 | 2024 | 197 | 0.860 |
Why?
|
| Cross-Sectional Studies | 27 | 2026 | 3834 | 0.860 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2018 | 3412 | 0.850 |
Why?
|
| Parenting | 3 | 2018 | 349 | 0.850 |
Why?
|
| Cooking | 2 | 2023 | 37 | 0.840 |
Why?
|
| Physical Fitness | 2 | 2023 | 89 | 0.840 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2015 | 902 | 0.840 |
Why?
|
| SAIDS Vaccines | 7 | 2019 | 12 | 0.840 |
Why?
|
| Adiposity | 12 | 2021 | 207 | 0.840 |
Why?
|
| Writing | 2 | 2024 | 60 | 0.830 |
Why?
|
| United States | 48 | 2026 | 11800 | 0.830 |
Why?
|
| Antipsychotic Agents | 8 | 2013 | 379 | 0.830 |
Why?
|
| Food Handling | 1 | 2023 | 14 | 0.820 |
Why?
|
| Dietary Sucrose | 3 | 2013 | 41 | 0.810 |
Why?
|
| Nutrition Assessment | 3 | 2021 | 125 | 0.800 |
Why?
|
| Satiation | 3 | 2024 | 27 | 0.800 |
Why?
|
| Evidence-Based Practice | 3 | 2018 | 116 | 0.790 |
Why?
|
| Soccer | 1 | 2023 | 8 | 0.790 |
Why?
|
| Genome-Wide Association Study | 6 | 2018 | 1840 | 0.790 |
Why?
|
| Creativity | 1 | 2023 | 13 | 0.790 |
Why?
|
| Risk Factors | 38 | 2026 | 10959 | 0.780 |
Why?
|
| Affective Symptoms | 1 | 2023 | 62 | 0.780 |
Why?
|
| Appetite | 1 | 2023 | 38 | 0.780 |
Why?
|
| Perception | 6 | 2021 | 228 | 0.780 |
Why?
|
| Body Height | 10 | 2016 | 196 | 0.770 |
Why?
|
| Actinidia | 1 | 2022 | 3 | 0.770 |
Why?
|
| Polymorphism, Genetic | 7 | 2006 | 794 | 0.770 |
Why?
|
| Music | 1 | 2023 | 18 | 0.770 |
Why?
|
| Information Dissemination | 2 | 2025 | 195 | 0.760 |
Why?
|
| Young Adult | 27 | 2024 | 10094 | 0.760 |
Why?
|
| Genome, Human | 8 | 2015 | 1332 | 0.760 |
Why?
|
| Body Constitution | 11 | 2005 | 42 | 0.760 |
Why?
|
| Mannans | 2 | 2015 | 14 | 0.760 |
Why?
|
| Health Education | 2 | 2015 | 229 | 0.760 |
Why?
|
| Models, Theoretical | 5 | 2018 | 366 | 0.760 |
Why?
|
| Prunus dulcis | 1 | 2022 | 1 | 0.760 |
Why?
|
| Computational Biology | 7 | 2015 | 872 | 0.750 |
Why?
|
| Ascorbic Acid | 1 | 2022 | 71 | 0.750 |
Why?
|
| Solanum tuberosum | 1 | 2022 | 12 | 0.750 |
Why?
|
| Pilot Projects | 8 | 2023 | 1453 | 0.740 |
Why?
|
| Muscle, Skeletal | 10 | 2021 | 1002 | 0.740 |
Why?
|
| Quantitative Trait, Heritable | 6 | 2011 | 106 | 0.740 |
Why?
|
| Elephants | 5 | 2025 | 46 | 0.730 |
Why?
|
| Child Nutritional Physiological Phenomena | 4 | 2015 | 157 | 0.730 |
Why?
|
| Carbonated Beverages | 2 | 2013 | 11 | 0.730 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2021 | 13 | 0.720 |
Why?
|
| Educational Status | 3 | 2023 | 281 | 0.710 |
Why?
|
| Research Support as Topic | 3 | 2011 | 61 | 0.710 |
Why?
|
| Phytotherapy | 3 | 2015 | 46 | 0.700 |
Why?
|
| Circadian Rhythm | 2 | 2022 | 315 | 0.690 |
Why?
|
| Wearable Electronic Devices | 1 | 2023 | 116 | 0.690 |
Why?
|
| Diet, Carbohydrate Loading | 1 | 2021 | 3 | 0.690 |
Why?
|
| Evidence-Based Medicine | 5 | 2017 | 644 | 0.680 |
Why?
|
| Food Supply | 2 | 2023 | 91 | 0.680 |
Why?
|
| Gene Expression Profiling | 15 | 2016 | 1833 | 0.680 |
Why?
|
| Coffee | 1 | 2021 | 30 | 0.670 |
Why?
|
| Consensus | 4 | 2023 | 565 | 0.670 |
Why?
|
| Clinical Trials as Topic | 6 | 2022 | 1139 | 0.660 |
Why?
|
| Insulin | 14 | 2024 | 1151 | 0.660 |
Why?
|
| Blueberry Plants | 1 | 2020 | 6 | 0.660 |
Why?
|
| Diet, Paleolithic | 1 | 2020 | 1 | 0.660 |
Why?
|
| Food Preferences | 5 | 2017 | 114 | 0.660 |
Why?
|
| Food Deprivation | 2 | 2019 | 34 | 0.650 |
Why?
|
| Mothers | 2 | 2023 | 371 | 0.650 |
Why?
|
| Moxibustion | 1 | 2020 | 1 | 0.640 |
Why?
|
| Plant Extracts | 2 | 2021 | 139 | 0.640 |
Why?
|
| Auriculotherapy | 1 | 2020 | 1 | 0.640 |
Why?
|
| United States Environmental Protection Agency | 1 | 2020 | 7 | 0.640 |
Why?
|
| Self Report | 8 | 2019 | 558 | 0.640 |
Why?
|
| Goals | 4 | 2020 | 125 | 0.640 |
Why?
|
| Cannabinoids | 1 | 2020 | 32 | 0.640 |
Why?
|
| Phenotype | 28 | 2021 | 4516 | 0.640 |
Why?
|
| Social Marketing | 1 | 2020 | 9 | 0.640 |
Why?
|
| Genetic Techniques | 5 | 2009 | 99 | 0.630 |
Why?
|
| Nuclear Family | 1 | 2020 | 49 | 0.630 |
Why?
|
| Correspondence as Topic | 1 | 2020 | 12 | 0.630 |
Why?
|
| Data Collection | 3 | 2018 | 371 | 0.630 |
Why?
|
| Research Personnel | 2 | 2020 | 139 | 0.630 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2024 | 323 | 0.630 |
Why?
|
| Genetic Variation | 10 | 2012 | 1556 | 0.630 |
Why?
|
| Government Regulation | 1 | 2020 | 44 | 0.620 |
Why?
|
| Terminology as Topic | 4 | 2010 | 227 | 0.620 |
Why?
|
| Pyrus | 1 | 2019 | 1 | 0.620 |
Why?
|
| Indians, North American | 1 | 2020 | 74 | 0.620 |
Why?
|
| Olea | 1 | 2019 | 2 | 0.620 |
Why?
|
| Hospital Design and Construction | 4 | 2025 | 12 | 0.620 |
Why?
|
| Bayes Theorem | 11 | 2024 | 306 | 0.610 |
Why?
|
| Cocos | 1 | 2019 | 3 | 0.610 |
Why?
|
| Episiotomy | 1 | 2019 | 17 | 0.610 |
Why?
|
| Tea | 1 | 2019 | 18 | 0.610 |
Why?
|
| Circadian Clocks | 1 | 2020 | 86 | 0.600 |
Why?
|
| Interior Design and Furnishings | 3 | 2025 | 4 | 0.600 |
Why?
|
| Fathers | 1 | 2020 | 71 | 0.600 |
Why?
|
| Epistasis, Genetic | 8 | 2008 | 98 | 0.600 |
Why?
|
| Child Nutrition Sciences | 1 | 2019 | 18 | 0.600 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1306 | 0.600 |
Why?
|
| Genotype | 21 | 2021 | 2655 | 0.590 |
Why?
|
| Snacks | 1 | 2019 | 20 | 0.590 |
Why?
|
| Kynurenine | 1 | 2019 | 26 | 0.590 |
Why?
|
| Heredity | 2 | 2018 | 15 | 0.580 |
Why?
|
| Nutrition Surveys | 12 | 2016 | 327 | 0.580 |
Why?
|
| Vitamin D | 1 | 2020 | 194 | 0.580 |
Why?
|
| Cardiovascular System | 1 | 2020 | 103 | 0.580 |
Why?
|
| Metabolic Syndrome | 4 | 2015 | 363 | 0.580 |
Why?
|
| Motivational Interviewing | 1 | 2019 | 51 | 0.580 |
Why?
|
| Video Games | 1 | 2020 | 97 | 0.570 |
Why?
|
| Accidents, Traffic | 4 | 2013 | 105 | 0.570 |
Why?
|
| Genomics | 5 | 2007 | 1624 | 0.570 |
Why?
|
| Physical Endurance | 3 | 2015 | 42 | 0.570 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2018 | 18 | 0.560 |
Why?
|
| Operating Rooms | 4 | 2025 | 76 | 0.560 |
Why?
|
| Linkage Disequilibrium | 6 | 2009 | 318 | 0.560 |
Why?
|
| Home Care Services | 1 | 2019 | 69 | 0.560 |
Why?
|
| Models, Educational | 1 | 2018 | 75 | 0.560 |
Why?
|
| Homosexuality, Female | 1 | 2018 | 3 | 0.560 |
Why?
|
| Pregnancy Complications | 1 | 2023 | 547 | 0.560 |
Why?
|
| Photography | 1 | 2018 | 80 | 0.550 |
Why?
|
| Air Pollution, Indoor | 1 | 2018 | 82 | 0.540 |
Why?
|
| Histocompatibility Antigens Class I | 9 | 2019 | 115 | 0.540 |
Why?
|
| Nutritional Physiological Phenomena | 4 | 2016 | 85 | 0.540 |
Why?
|
| Policy Making | 2 | 2017 | 59 | 0.540 |
Why?
|
| Genetics | 2 | 2009 | 24 | 0.530 |
Why?
|
| Maternal Behavior | 2 | 2015 | 70 | 0.530 |
Why?
|
| Meta-Analysis as Topic | 4 | 2008 | 169 | 0.520 |
Why?
|
| Diet, Fat-Restricted | 3 | 2015 | 37 | 0.520 |
Why?
|
| Cause of Death | 6 | 2019 | 510 | 0.510 |
Why?
|
| Sex Factors | 19 | 2024 | 1346 | 0.510 |
Why?
|
| Macaca mulatta | 20 | 2019 | 496 | 0.510 |
Why?
|
| Treatment Outcome | 16 | 2025 | 12964 | 0.510 |
Why?
|
| Demography | 1 | 2017 | 243 | 0.510 |
Why?
|
| Sexual and Gender Minorities | 1 | 2018 | 68 | 0.500 |
Why?
|
| Gastric Bypass | 1 | 2017 | 96 | 0.500 |
Why?
|
| Cognition | 6 | 2024 | 843 | 0.500 |
Why?
|
| Hunger | 3 | 2013 | 42 | 0.500 |
Why?
|
| Life Style | 7 | 2023 | 444 | 0.490 |
Why?
|
| Risk | 4 | 2013 | 739 | 0.490 |
Why?
|
| Public Health Systems Research | 1 | 2016 | 1 | 0.490 |
Why?
|
| Fructose | 3 | 2011 | 61 | 0.490 |
Why?
|
| Brassica | 1 | 2016 | 17 | 0.490 |
Why?
|
| Dietary Fiber | 2 | 2015 | 78 | 0.490 |
Why?
|
| Law Enforcement | 1 | 2016 | 18 | 0.480 |
Why?
|
| Diabetes Mellitus | 7 | 2023 | 890 | 0.480 |
Why?
|
| Insulin Resistance | 6 | 2022 | 681 | 0.480 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 404 | 0.480 |
Why?
|
| Police | 1 | 2016 | 14 | 0.480 |
Why?
|
| Gene Expression | 3 | 2019 | 1501 | 0.470 |
Why?
|
| Fast Foods | 2 | 2014 | 23 | 0.470 |
Why?
|
| Alleles | 12 | 2018 | 1708 | 0.470 |
Why?
|
| Cytokines | 2 | 2019 | 1347 | 0.470 |
Why?
|
| Postprandial Period | 2 | 2019 | 86 | 0.470 |
Why?
|
| Genetic Markers | 10 | 2012 | 605 | 0.470 |
Why?
|
| Rats | 11 | 2022 | 3460 | 0.460 |
Why?
|
| Amorphophallus | 1 | 2015 | 1 | 0.460 |
Why?
|
| Phentermine | 2 | 2011 | 7 | 0.450 |
Why?
|
| Rehabilitation | 1 | 2015 | 24 | 0.450 |
Why?
|
| Food Labeling | 2 | 2011 | 11 | 0.450 |
Why?
|
| Proportional Hazards Models | 8 | 2025 | 1405 | 0.450 |
Why?
|
| Sleep Deprivation | 1 | 2015 | 44 | 0.450 |
Why?
|
| Restaurants | 1 | 2014 | 13 | 0.450 |
Why?
|
| Cross-Over Studies | 7 | 2019 | 331 | 0.440 |
Why?
|
| Play and Playthings | 1 | 2014 | 17 | 0.440 |
Why?
|
| Publications | 2 | 2014 | 36 | 0.440 |
Why?
|
| Patient Participation | 2 | 2015 | 244 | 0.440 |
Why?
|
| DNA, Mitochondrial | 3 | 2021 | 241 | 0.430 |
Why?
|
| Publication Bias | 3 | 2017 | 17 | 0.430 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 230 | 0.430 |
Why?
|
| Crowdsourcing | 1 | 2014 | 14 | 0.430 |
Why?
|
| Poverty | 2 | 2017 | 455 | 0.430 |
Why?
|
| Nuts | 1 | 2014 | 15 | 0.430 |
Why?
|
| Life Tables | 2 | 2012 | 27 | 0.420 |
Why?
|
| Analysis of Variance | 12 | 2015 | 955 | 0.420 |
Why?
|
| Fabaceae | 1 | 2014 | 19 | 0.420 |
Why?
|
| Quality of Life | 5 | 2023 | 2113 | 0.420 |
Why?
|
| Genetics, Population | 4 | 2010 | 185 | 0.420 |
Why?
|
| Diagnostic Self Evaluation | 2 | 2012 | 21 | 0.420 |
Why?
|
| Surveys and Questionnaires | 10 | 2025 | 4039 | 0.420 |
Why?
|
| Water Supply | 1 | 2013 | 26 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 15 | 2016 | 2862 | 0.410 |
Why?
|
| Private Sector | 1 | 2013 | 26 | 0.410 |
Why?
|
| Comprehension | 1 | 2014 | 76 | 0.410 |
Why?
|
| Reproductive Behavior | 1 | 2013 | 7 | 0.410 |
Why?
|
| Body Fat Distribution | 2 | 2011 | 32 | 0.410 |
Why?
|
| Critical Illness | 1 | 2018 | 615 | 0.410 |
Why?
|
| Behavior, Animal | 3 | 2021 | 510 | 0.410 |
Why?
|
| Gait | 1 | 2015 | 146 | 0.410 |
Why?
|
| Depression | 1 | 2023 | 1338 | 0.410 |
Why?
|
| Facility Design and Construction | 2 | 2025 | 6 | 0.410 |
Why?
|
| Stress, Psychological | 2 | 2018 | 562 | 0.410 |
Why?
|
| Calorimetry, Indirect | 7 | 2025 | 65 | 0.410 |
Why?
|
| Autism Spectrum Disorder | 1 | 2019 | 438 | 0.400 |
Why?
|
| Longitudinal Studies | 13 | 2024 | 1516 | 0.400 |
Why?
|
| Diet, High-Fat | 3 | 2024 | 264 | 0.400 |
Why?
|
| Gene Products, vif | 3 | 2019 | 7 | 0.400 |
Why?
|
| Cholesterol, LDL | 2 | 2015 | 612 | 0.400 |
Why?
|
| Authorship | 1 | 2013 | 29 | 0.400 |
Why?
|
| Deoxyglucose | 2 | 2010 | 42 | 0.400 |
Why?
|
| Gene Products, nef | 3 | 2019 | 17 | 0.400 |
Why?
|
| Monte Carlo Method | 4 | 2025 | 103 | 0.390 |
Why?
|
| Genome | 2 | 2006 | 472 | 0.390 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 129 | 0.390 |
Why?
|
| Cookbooks as Topic | 1 | 2012 | 2 | 0.390 |
Why?
|
| Appetite Depressants | 2 | 2010 | 23 | 0.390 |
Why?
|
| Crohn Disease | 1 | 2016 | 291 | 0.380 |
Why?
|
| Epidemiologic Studies | 2 | 2010 | 41 | 0.380 |
Why?
|
| Cold Temperature | 3 | 2018 | 81 | 0.380 |
Why?
|
| Walking | 1 | 2015 | 234 | 0.380 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2025 | 68 | 0.380 |
Why?
|
| Needs Assessment | 1 | 2013 | 173 | 0.380 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 6922 | 0.380 |
Why?
|
| Pregnancy | 7 | 2024 | 7572 | 0.370 |
Why?
|
| Drug Approval | 1 | 2012 | 45 | 0.370 |
Why?
|
| Glutamate Decarboxylase | 2 | 2018 | 43 | 0.370 |
Why?
|
| Abdominal Fat | 2 | 2013 | 24 | 0.370 |
Why?
|
| Plethysmography | 1 | 2012 | 34 | 0.370 |
Why?
|
| Fertility | 2 | 2016 | 266 | 0.370 |
Why?
|
| Air | 1 | 2012 | 22 | 0.360 |
Why?
|
| Medication Adherence | 1 | 2015 | 334 | 0.360 |
Why?
|
| Inflammation | 2 | 2021 | 1492 | 0.360 |
Why?
|
| Blood Pressure | 8 | 2016 | 1344 | 0.360 |
Why?
|
| Lipoproteins, LDL | 2 | 2011 | 118 | 0.360 |
Why?
|
| Chronic Disease | 1 | 2016 | 1234 | 0.360 |
Why?
|
| Models, Animal | 5 | 2018 | 460 | 0.360 |
Why?
|
| Adoption | 1 | 2011 | 18 | 0.360 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 463 | 0.360 |
Why?
|
| Family | 5 | 2022 | 589 | 0.350 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2019 | 460 | 0.350 |
Why?
|
| Drosophila melanogaster | 5 | 2018 | 846 | 0.350 |
Why?
|
| Mental Disorders | 3 | 2025 | 901 | 0.350 |
Why?
|
| Algorithms | 10 | 2014 | 1686 | 0.350 |
Why?
|
| Heart Rate | 3 | 2023 | 580 | 0.350 |
Why?
|
| Workflow | 4 | 2025 | 139 | 0.350 |
Why?
|
| Body Temperature | 4 | 2024 | 128 | 0.350 |
Why?
|
| Absorptiometry, Photon | 15 | 2017 | 199 | 0.350 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 310 | 0.350 |
Why?
|
| Basal Metabolism | 6 | 2013 | 93 | 0.350 |
Why?
|
| Age Factors | 14 | 2021 | 2872 | 0.340 |
Why?
|
| Diseases in Twins | 3 | 2005 | 90 | 0.340 |
Why?
|
| National Institute on Aging (U.S.) | 2 | 2026 | 8 | 0.340 |
Why?
|
| Depressive Disorder | 1 | 2014 | 467 | 0.340 |
Why?
|
| Cyclobutanes | 1 | 2010 | 7 | 0.340 |
Why?
|
| Rats, Inbred F344 | 2 | 2010 | 99 | 0.340 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2009 | 267 | 0.330 |
Why?
|
| Dioxins | 1 | 2010 | 4 | 0.330 |
Why?
|
| Telomere | 3 | 2019 | 220 | 0.330 |
Why?
|
| Pediatrics | 2 | 2025 | 1231 | 0.330 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2010 | 12 | 0.330 |
Why?
|
| Primary Health Care | 2 | 2021 | 787 | 0.330 |
Why?
|
| Motor Vehicles | 1 | 2010 | 10 | 0.320 |
Why?
|
| Biomimetics | 1 | 2010 | 18 | 0.320 |
Why?
|
| Stilbenes | 1 | 2010 | 36 | 0.320 |
Why?
|
| Double-Blind Method | 7 | 2019 | 1634 | 0.320 |
Why?
|
| Infant | 10 | 2026 | 13305 | 0.320 |
Why?
|
| Wounds and Injuries | 2 | 2012 | 396 | 0.310 |
Why?
|
| Guidelines as Topic | 3 | 2019 | 200 | 0.310 |
Why?
|
| Software | 5 | 2012 | 752 | 0.310 |
Why?
|
| Endocrine Disruptors | 1 | 2010 | 55 | 0.310 |
Why?
|
| Glucose | 6 | 2022 | 848 | 0.310 |
Why?
|
| Patient Compliance | 5 | 2014 | 469 | 0.310 |
Why?
|
| Temperature | 3 | 2018 | 294 | 0.310 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 432 | 0.310 |
Why?
|
| Body Size | 4 | 2019 | 59 | 0.310 |
Why?
|
| Child, Preschool | 19 | 2026 | 15054 | 0.300 |
Why?
|
| Homeostasis | 5 | 2018 | 713 | 0.300 |
Why?
|
| Thermogenesis | 2 | 2020 | 55 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2010 | 87 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 2648 | 0.300 |
Why?
|
| Language | 1 | 2010 | 218 | 0.290 |
Why?
|
| Logistic Models | 8 | 2013 | 1831 | 0.290 |
Why?
|
| Gene Expression Regulation | 9 | 2021 | 2356 | 0.290 |
Why?
|
| Prevalence | 12 | 2026 | 2694 | 0.290 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 743 | 0.290 |
Why?
|
| Attitude to Health | 2 | 2003 | 251 | 0.290 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 455 | 0.290 |
Why?
|
| Virus Replication | 7 | 2018 | 597 | 0.290 |
Why?
|
| Crosses, Genetic | 6 | 2006 | 155 | 0.290 |
Why?
|
| Industry | 1 | 2008 | 29 | 0.290 |
Why?
|
| Acclimatization | 3 | 2018 | 21 | 0.280 |
Why?
|
| Observation | 1 | 2008 | 39 | 0.280 |
Why?
|
| Soy Foods | 1 | 2008 | 2 | 0.280 |
Why?
|
| Patients | 1 | 2009 | 122 | 0.280 |
Why?
|
| Schizophrenia | 2 | 2003 | 331 | 0.280 |
Why?
|
| Parent-Child Relations | 3 | 2014 | 255 | 0.280 |
Why?
|
| Acarbose | 2 | 2020 | 7 | 0.270 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 5296 | 0.270 |
Why?
|
| Birth Weight | 2 | 2023 | 346 | 0.270 |
Why?
|
| Suicide, Attempted | 1 | 2009 | 153 | 0.270 |
Why?
|
| Odds Ratio | 8 | 2016 | 1235 | 0.270 |
Why?
|
| Glucose Tolerance Test | 3 | 2024 | 200 | 0.270 |
Why?
|
| Smoking Cessation | 2 | 2006 | 190 | 0.270 |
Why?
|
| Corn Oil | 1 | 2007 | 10 | 0.270 |
Why?
|
| Metabolism | 2 | 2013 | 45 | 0.270 |
Why?
|
| Survival Analysis | 7 | 2014 | 1521 | 0.260 |
Why?
|
| Gene Frequency | 7 | 2015 | 750 | 0.260 |
Why?
|
| Headache | 1 | 2008 | 110 | 0.260 |
Why?
|
| Twins, Monozygotic | 5 | 2012 | 125 | 0.260 |
Why?
|
| Alzheimer Disease | 3 | 2015 | 875 | 0.260 |
Why?
|
| Databases, Genetic | 2 | 2008 | 500 | 0.260 |
Why?
|
| Disease | 1 | 2008 | 125 | 0.260 |
Why?
|
| Oxidative Stress | 4 | 2024 | 807 | 0.250 |
Why?
|
| Triiodothyronine | 2 | 2025 | 56 | 0.250 |
Why?
|
| Suicide | 1 | 2009 | 203 | 0.250 |
Why?
|
| Biomarkers | 10 | 2026 | 3405 | 0.250 |
Why?
|
| Ethics, Research | 2 | 2024 | 54 | 0.250 |
Why?
|
| Cattle | 2 | 2025 | 521 | 0.250 |
Why?
|
| Bupropion | 1 | 2006 | 27 | 0.250 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2006 | 36 | 0.250 |
Why?
|
| Food, Formulated | 2 | 2024 | 38 | 0.250 |
Why?
|
| Socioeconomic Factors | 4 | 2023 | 897 | 0.250 |
Why?
|
| Carrier Proteins | 2 | 2002 | 1024 | 0.250 |
Why?
|
| Bone Density | 7 | 2012 | 363 | 0.250 |
Why?
|
| Animals, Zoo | 3 | 2023 | 17 | 0.240 |
Why?
|
| Genes | 1 | 2007 | 308 | 0.240 |
Why?
|
| Uric Acid | 2 | 2018 | 110 | 0.240 |
Why?
|
| Hyperinsulinism | 2 | 2022 | 58 | 0.240 |
Why?
|
| Vaccination | 6 | 2026 | 1040 | 0.240 |
Why?
|
| Likelihood Functions | 7 | 2009 | 117 | 0.240 |
Why?
|
| Health Surveys | 6 | 2013 | 262 | 0.240 |
Why?
|
| Stroke | 1 | 2014 | 1049 | 0.240 |
Why?
|
| Smoking | 4 | 2012 | 926 | 0.240 |
Why?
|
| Physicians | 2 | 2024 | 634 | 0.240 |
Why?
|
| Risperidone | 4 | 2013 | 61 | 0.240 |
Why?
|
| Adenoviridae Infections | 3 | 2013 | 76 | 0.240 |
Why?
|
| Patients' Rooms | 1 | 2025 | 8 | 0.230 |
Why?
|
| Time Factors | 11 | 2018 | 6279 | 0.230 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 1023 | 0.230 |
Why?
|
| Red Meat | 1 | 2025 | 7 | 0.230 |
Why?
|
| Morbidity | 2 | 2025 | 260 | 0.230 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2005 | 13 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2005 | 68 | 0.230 |
Why?
|
| Synephrine | 1 | 2005 | 1 | 0.230 |
Why?
|
| Cohort Studies | 11 | 2013 | 5123 | 0.230 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2026 | 90 | 0.230 |
Why?
|
| Citrus | 1 | 2005 | 5 | 0.230 |
Why?
|
| Mexico | 1 | 2026 | 198 | 0.230 |
Why?
|
| HIV-1 | 4 | 2017 | 477 | 0.230 |
Why?
|
| Parents | 3 | 2019 | 1109 | 0.230 |
Why?
|
| Oxygen Consumption | 4 | 2015 | 301 | 0.230 |
Why?
|
| Trust | 1 | 2026 | 81 | 0.230 |
Why?
|
| Disease Outbreaks | 2 | 2006 | 314 | 0.230 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2026 | 75 | 0.230 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2024 | 97 | 0.230 |
Why?
|
| Biology | 1 | 2005 | 25 | 0.230 |
Why?
|
| Proteomics | 2 | 2006 | 607 | 0.220 |
Why?
|
| Alkaloids | 1 | 2005 | 36 | 0.220 |
Why?
|
| Adaptation, Physiological | 3 | 2022 | 261 | 0.220 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2016 | 81 | 0.220 |
Why?
|
| Prospective Studies | 13 | 2026 | 6494 | 0.220 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 904 | 0.220 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 107 | 0.220 |
Why?
|
| Plants, Medicinal | 1 | 2004 | 24 | 0.220 |
Why?
|
| Gene Products, gag | 3 | 2014 | 20 | 0.220 |
Why?
|
| Skin Aging | 1 | 2024 | 12 | 0.220 |
Why?
|
| Pyrazoles | 2 | 2026 | 358 | 0.220 |
Why?
|
| Nonprescription Drugs | 1 | 2005 | 54 | 0.220 |
Why?
|
| Antibodies, Viral | 7 | 2022 | 1169 | 0.220 |
Why?
|
| Sex Characteristics | 4 | 2016 | 338 | 0.220 |
Why?
|
| Narration | 1 | 2024 | 33 | 0.220 |
Why?
|
| Knowledge | 1 | 2004 | 50 | 0.210 |
Why?
|
| Sexual Behavior | 1 | 2006 | 245 | 0.210 |
Why?
|
| Neoplasms | 5 | 2018 | 2969 | 0.210 |
Why?
|
| Disease Models, Animal | 10 | 2022 | 4696 | 0.210 |
Why?
|
| Maternal Health | 1 | 2024 | 28 | 0.210 |
Why?
|
| Root Resorption | 1 | 2024 | 1 | 0.210 |
Why?
|
| Twins | 2 | 1994 | 71 | 0.210 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2004 | 26 | 0.210 |
Why?
|
| Molecular Biology | 1 | 2004 | 68 | 0.210 |
Why?
|
| Mental Processes | 1 | 2024 | 38 | 0.210 |
Why?
|
| Rest | 3 | 2010 | 63 | 0.210 |
Why?
|
| Child Development | 3 | 2017 | 272 | 0.210 |
Why?
|
| Interferon Regulatory Factors | 1 | 2024 | 46 | 0.210 |
Why?
|
| Bone Resorption | 1 | 2024 | 50 | 0.210 |
Why?
|
| Gene Products, env | 2 | 2018 | 16 | 0.210 |
Why?
|
| Mitochondria | 5 | 2021 | 759 | 0.210 |
Why?
|
| Leptin | 5 | 2024 | 219 | 0.200 |
Why?
|
| Twins, Dizygotic | 4 | 2012 | 46 | 0.200 |
Why?
|
| Problem Solving | 1 | 2023 | 65 | 0.200 |
Why?
|
| Mexican Americans | 1 | 2004 | 166 | 0.200 |
Why?
|
| Brazil | 1 | 2023 | 140 | 0.200 |
Why?
|
| Costs and Cost Analysis | 2 | 2018 | 155 | 0.200 |
Why?
|
| Glucocorticoids | 2 | 2025 | 350 | 0.200 |
Why?
|
| Medicaid | 1 | 2026 | 252 | 0.200 |
Why?
|
| Dairy Products | 2 | 2020 | 43 | 0.200 |
Why?
|
| Nicaragua | 1 | 2023 | 27 | 0.200 |
Why?
|
| Thailand | 1 | 2023 | 45 | 0.200 |
Why?
|
| Canada | 2 | 2022 | 327 | 0.190 |
Why?
|
| Sex Distribution | 4 | 2013 | 322 | 0.190 |
Why?
|
| Mentors | 1 | 2024 | 160 | 0.190 |
Why?
|
| Quality Control | 2 | 2018 | 118 | 0.190 |
Why?
|
| Tablets | 1 | 2022 | 38 | 0.190 |
Why?
|
| Hyperphagia | 2 | 2013 | 46 | 0.190 |
Why?
|
| New York | 3 | 2016 | 69 | 0.190 |
Why?
|
| Predictive Value of Tests | 5 | 2015 | 2297 | 0.190 |
Why?
|
| Glucosides | 2 | 2018 | 54 | 0.190 |
Why?
|
| Risk Assessment | 7 | 2026 | 3695 | 0.190 |
Why?
|
| Psychology, Child | 1 | 2002 | 43 | 0.190 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 185 | 0.190 |
Why?
|
| Glucose Intolerance | 2 | 2020 | 78 | 0.190 |
Why?
|
| Television | 1 | 2023 | 70 | 0.190 |
Why?
|
| Protein Isoforms | 2 | 2019 | 421 | 0.190 |
Why?
|
| Coronary Disease | 2 | 2025 | 638 | 0.190 |
Why?
|
| Haplotypes | 5 | 2010 | 543 | 0.180 |
Why?
|
| Piperidines | 1 | 2004 | 232 | 0.180 |
Why?
|
| Feces | 2 | 2025 | 725 | 0.180 |
Why?
|
| Decision Trees | 1 | 2022 | 57 | 0.180 |
Why?
|
| Pedigree | 4 | 2012 | 1710 | 0.180 |
Why?
|
| Metabolome | 2 | 2022 | 329 | 0.180 |
Why?
|
| Vitamins | 1 | 2022 | 115 | 0.180 |
Why?
|
| Caffeine | 2 | 2017 | 67 | 0.180 |
Why?
|
| Fasting | 2 | 2021 | 303 | 0.180 |
Why?
|
| Mental Health Services | 1 | 2025 | 272 | 0.180 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2021 | 20 | 0.180 |
Why?
|
| Decision Making | 3 | 2018 | 683 | 0.180 |
Why?
|
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2021 | 5 | 0.180 |
Why?
|
| Obesity Management | 1 | 2021 | 4 | 0.180 |
Why?
|
| Signal Transduction | 5 | 2021 | 4683 | 0.180 |
Why?
|
| Diet Therapy | 1 | 2021 | 41 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2018 | 1010 | 0.170 |
Why?
|
| Water | 1 | 2022 | 190 | 0.170 |
Why?
|
| Flavonols | 1 | 2021 | 11 | 0.170 |
Why?
|
| Counseling | 1 | 2023 | 237 | 0.170 |
Why?
|
| Osteoarthritis | 1 | 2023 | 104 | 0.170 |
Why?
|
| Child Behavior | 2 | 2014 | 236 | 0.170 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 128 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2025 | 557 | 0.170 |
Why?
|
| Canagliflozin | 1 | 2020 | 1 | 0.170 |
Why?
|
| Patient Handoff | 1 | 2021 | 23 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 459 | 0.170 |
Why?
|
| Fetus | 1 | 2024 | 585 | 0.170 |
Why?
|
| Age Distribution | 2 | 2016 | 429 | 0.170 |
Why?
|
| Anesthesia | 1 | 2023 | 210 | 0.170 |
Why?
|
| Macaca | 3 | 2010 | 60 | 0.170 |
Why?
|
| Cost of Illness | 1 | 2003 | 291 | 0.170 |
Why?
|
| Rectum | 2 | 2019 | 103 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2020 | 263 | 0.160 |
Why?
|
| Complementary Therapies | 1 | 2001 | 43 | 0.160 |
Why?
|
| Hippocampus | 2 | 2024 | 805 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2005 | 726 | 0.160 |
Why?
|
| Multivariate Analysis | 8 | 2014 | 1405 | 0.160 |
Why?
|
| Fatty Acids | 2 | 2017 | 362 | 0.160 |
Why?
|
| Death | 1 | 2001 | 77 | 0.160 |
Why?
|
| Lipids | 4 | 2008 | 565 | 0.160 |
Why?
|
| Recombination, Genetic | 1 | 2021 | 426 | 0.160 |
Why?
|
| Courage | 1 | 2020 | 4 | 0.160 |
Why?
|
| Tropism | 1 | 2019 | 9 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2023 | 376 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 33 | 0.160 |
Why?
|
| Intra-Abdominal Fat | 2 | 2012 | 64 | 0.160 |
Why?
|
| Keratins | 1 | 2019 | 51 | 0.160 |
Why?
|
| Probability | 2 | 2013 | 310 | 0.160 |
Why?
|
| Drug Combinations | 3 | 2011 | 277 | 0.150 |
Why?
|
| Access to Information | 2 | 2019 | 45 | 0.150 |
Why?
|
| Nutrition Policy | 3 | 2020 | 91 | 0.150 |
Why?
|
| Encephalitis | 1 | 2021 | 120 | 0.150 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2019 | 15 | 0.150 |
Why?
|
| Affect | 2 | 2019 | 170 | 0.150 |
Why?
|
| Siblings | 3 | 2012 | 204 | 0.150 |
Why?
|
| Fitness Trackers | 1 | 2019 | 15 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 300 | 0.150 |
Why?
|
| RNA, Messenger | 7 | 2008 | 2567 | 0.150 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2019 | 45 | 0.150 |
Why?
|
| Scientific Misconduct | 1 | 2019 | 6 | 0.150 |
Why?
|
| Engineering | 1 | 2019 | 7 | 0.150 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 218 | 0.150 |
Why?
|
| Emergency Service, Hospital | 2 | 2025 | 1217 | 0.150 |
Why?
|
| Least-Squares Analysis | 4 | 2012 | 29 | 0.150 |
Why?
|
| Congresses as Topic | 3 | 2014 | 186 | 0.150 |
Why?
|
| Telemedicine | 1 | 2025 | 519 | 0.150 |
Why?
|
| Diet Records | 2 | 2016 | 70 | 0.150 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 186 | 0.150 |
Why?
|
| Butylene Glycols | 1 | 2018 | 1 | 0.150 |
Why?
|
| Satiety Response | 4 | 2024 | 31 | 0.150 |
Why?
|
| Acetoacetates | 1 | 2018 | 14 | 0.150 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2019 | 42 | 0.150 |
Why?
|
| Receptors, Peptide | 1 | 1999 | 57 | 0.150 |
Why?
|
| Comorbidity | 3 | 2018 | 1595 | 0.150 |
Why?
|
| PPAR alpha | 1 | 2019 | 53 | 0.150 |
Why?
|
| Developed Countries | 1 | 2019 | 44 | 0.150 |
Why?
|
| Turkey | 1 | 2018 | 64 | 0.140 |
Why?
|
| Swimming | 1 | 2018 | 30 | 0.140 |
Why?
|
| Athletes | 2 | 2021 | 73 | 0.140 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2018 | 37 | 0.140 |
Why?
|
| Postmenopause | 1 | 2019 | 149 | 0.140 |
Why?
|
| Fibronectins | 1 | 2018 | 99 | 0.140 |
Why?
|
| Fenofibrate | 2 | 2009 | 59 | 0.140 |
Why?
|
| Skin | 2 | 2019 | 553 | 0.140 |
Why?
|
| Family Health | 2 | 2014 | 250 | 0.140 |
Why?
|
| Australian Capital Territory | 1 | 2017 | 2 | 0.140 |
Why?
|
| Health | 2 | 2012 | 35 | 0.140 |
Why?
|
| Weaning | 1 | 2018 | 52 | 0.140 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 93 | 0.140 |
Why?
|
| Estrous Cycle | 1 | 2018 | 40 | 0.140 |
Why?
|
| Patient Dropouts | 3 | 2015 | 50 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 303 | 0.140 |
Why?
|
| Genetics, Behavioral | 1 | 1997 | 8 | 0.130 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 8 | 0.130 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 134 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2019 | 132 | 0.130 |
Why?
|
| Self Concept | 1 | 1998 | 163 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2026 | 866 | 0.130 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 75 | 0.130 |
Why?
|
| Australia | 1 | 2017 | 176 | 0.130 |
Why?
|
| Triglycerides | 4 | 2012 | 605 | 0.130 |
Why?
|
| Adenosine Triphosphate | 1 | 2018 | 265 | 0.130 |
Why?
|
| Vaccines, Synthetic | 2 | 2019 | 321 | 0.130 |
Why?
|
| Taste Threshold | 1 | 2017 | 1 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2018 | 132 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2014 | 1224 | 0.130 |
Why?
|
| Growth Hormone | 1 | 2017 | 127 | 0.130 |
Why?
|
| Receptors, Fc | 1 | 2016 | 29 | 0.130 |
Why?
|
| Taste | 1 | 2017 | 28 | 0.130 |
Why?
|
| Arousal | 1 | 2017 | 77 | 0.130 |
Why?
|
| Caregivers | 1 | 2023 | 583 | 0.130 |
Why?
|
| Students | 1 | 2019 | 251 | 0.130 |
Why?
|
| Surface Plasmon Resonance | 1 | 2016 | 54 | 0.130 |
Why?
|
| Surgeons | 1 | 2021 | 287 | 0.130 |
Why?
|
| Hypolipidemic Agents | 2 | 2009 | 194 | 0.130 |
Why?
|
| Pharmacogenetics | 3 | 2009 | 203 | 0.130 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2016 | 12 | 0.130 |
Why?
|
| Hepacivirus | 1 | 2018 | 273 | 0.130 |
Why?
|
| Cognition Disorders | 1 | 2021 | 565 | 0.130 |
Why?
|
| Psychological Tests | 1 | 1997 | 94 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 2143 | 0.120 |
Why?
|
| Epidemiologic Methods | 1 | 2016 | 95 | 0.120 |
Why?
|
| Social Stigma | 1 | 2017 | 82 | 0.120 |
Why?
|
| Alabama | 6 | 2016 | 44 | 0.120 |
Why?
|
| Visual Analog Scale | 1 | 2016 | 8 | 0.120 |
Why?
|
| Parks, Recreational | 1 | 2016 | 5 | 0.120 |
Why?
|
| Pain | 1 | 2019 | 439 | 0.120 |
Why?
|
| Skinfold Thickness | 3 | 2003 | 34 | 0.120 |
Why?
|
| Adipokines | 1 | 2017 | 121 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 129 | 0.120 |
Why?
|
| Hormones | 1 | 2017 | 165 | 0.120 |
Why?
|
| Proteins | 3 | 2014 | 1027 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 366 | 0.120 |
Why?
|
| Biosensing Techniques | 1 | 2016 | 75 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 354 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2018 | 397 | 0.120 |
Why?
|
| Down Syndrome | 2 | 1995 | 233 | 0.120 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 1298 | 0.120 |
Why?
|
| Diet, Mediterranean | 1 | 2015 | 19 | 0.120 |
Why?
|
| Acupressure | 1 | 1995 | 1 | 0.120 |
Why?
|
| Principal Component Analysis | 2 | 2026 | 153 | 0.120 |
Why?
|
| Programming Languages | 2 | 2006 | 19 | 0.120 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2015 | 50 | 0.120 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2015 | 33 | 0.120 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2015 | 37 | 0.120 |
Why?
|
| Ear, External | 1 | 1995 | 25 | 0.120 |
Why?
|
| Homozygote | 2 | 2009 | 547 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2019 | 314 | 0.120 |
Why?
|
| Wound Healing | 1 | 2019 | 476 | 0.110 |
Why?
|
| Reimbursement, Incentive | 2 | 2007 | 48 | 0.110 |
Why?
|
| Spouses | 1 | 1996 | 70 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 1151 | 0.110 |
Why?
|
| Hyperuricemia | 1 | 2015 | 38 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1161 | 0.110 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 125 | 0.110 |
Why?
|
| HIV Infections | 4 | 2017 | 2037 | 0.110 |
Why?
|
| Meals | 3 | 2023 | 62 | 0.110 |
Why?
|
| Macrophages | 1 | 2019 | 666 | 0.110 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 390 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2019 | 2436 | 0.110 |
Why?
|
| Pregnancy, Animal | 1 | 2015 | 69 | 0.110 |
Why?
|
| Locomotion | 1 | 2015 | 59 | 0.110 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 128 | 0.110 |
Why?
|
| Health Services Research | 1 | 2016 | 178 | 0.110 |
Why?
|
| Delayed-Action Preparations | 2 | 2011 | 119 | 0.110 |
Why?
|
| Reference Values | 6 | 2016 | 692 | 0.110 |
Why?
|
| Antioxidants | 2 | 2015 | 336 | 0.110 |
Why?
|
| Viremia | 3 | 2019 | 132 | 0.110 |
Why?
|
| Osteoporosis | 2 | 2011 | 134 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2018 | 390 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2015 | 220 | 0.110 |
Why?
|
| Brain Injuries | 1 | 2019 | 711 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2012 | 320 | 0.110 |
Why?
|
| Hypertension | 2 | 2011 | 1360 | 0.110 |
Why?
|
| Altitude | 1 | 2014 | 23 | 0.110 |
Why?
|
| Newfoundland and Labrador | 1 | 2013 | 3 | 0.110 |
Why?
|
| Paternal Behavior | 1 | 2014 | 12 | 0.110 |
Why?
|
| Portion Size | 1 | 2014 | 17 | 0.100 |
Why?
|
| Masoprocol | 1 | 2013 | 7 | 0.100 |
Why?
|
| Water Microbiology | 1 | 2013 | 28 | 0.100 |
Why?
|
| Species Specificity | 3 | 2010 | 519 | 0.100 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 34 | 0.100 |
Why?
|
| Twin Studies as Topic | 2 | 2008 | 13 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2011 | 120 | 0.100 |
Why?
|
| United States Food and Drug Administration | 2 | 2012 | 156 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 2017 | 529 | 0.100 |
Why?
|
| Child Restraint Systems | 1 | 2013 | 6 | 0.100 |
Why?
|
| Mice, Inbred Strains | 4 | 2021 | 297 | 0.100 |
Why?
|
| Dasatinib | 2 | 2026 | 53 | 0.100 |
Why?
|
| Adenoviruses, Human | 2 | 2005 | 97 | 0.100 |
Why?
|
| Sirtuin 1 | 1 | 2014 | 56 | 0.100 |
Why?
|
| Body Image | 1 | 1993 | 39 | 0.100 |
Why?
|
| Seat Belts | 1 | 2013 | 24 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2013 | 56 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2016 | 983 | 0.100 |
Why?
|
| Apolipoprotein A-I | 3 | 2016 | 80 | 0.100 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2009 | 286 | 0.100 |
Why?
|
| Deuterium | 3 | 2022 | 95 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 228 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 1745 | 0.100 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2006 | 517 | 0.090 |
Why?
|
| ROC Curve | 2 | 2012 | 615 | 0.090 |
Why?
|
| Normal Distribution | 1 | 2012 | 19 | 0.090 |
Why?
|
| Internet | 2 | 2006 | 419 | 0.090 |
Why?
|
| Gout | 1 | 2015 | 173 | 0.090 |
Why?
|
| Isotopes | 1 | 2012 | 25 | 0.090 |
Why?
|
| Indicator Dilution Techniques | 1 | 2012 | 24 | 0.090 |
Why?
|
| Heart Diseases | 2 | 2007 | 505 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2009 | 3454 | 0.090 |
Why?
|
| Body Water | 1 | 2012 | 88 | 0.090 |
Why?
|
| Nutritive Value | 1 | 2012 | 83 | 0.090 |
Why?
|
| Receptors, Leptin | 2 | 2002 | 41 | 0.090 |
Why?
|
| Thiazoles | 2 | 2005 | 109 | 0.090 |
Why?
|
| Brain | 3 | 2015 | 3238 | 0.090 |
Why?
|
| Incidence | 5 | 2026 | 3347 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 630 | 0.090 |
Why?
|
| Urban Health | 2 | 2014 | 85 | 0.090 |
Why?
|
| Disease Progression | 2 | 2026 | 2206 | 0.090 |
Why?
|
| Body Temperature Regulation | 2 | 2008 | 51 | 0.090 |
Why?
|
| Infant Formula | 2 | 2024 | 104 | 0.090 |
Why?
|
| Estradiol | 1 | 2013 | 481 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17666 | 0.090 |
Why?
|
| Menu Planning | 1 | 2011 | 8 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 482 | 0.090 |
Why?
|
| Callithrix | 1 | 2010 | 14 | 0.080 |
Why?
|
| Program Evaluation | 1 | 2013 | 441 | 0.080 |
Why?
|
| Rats, Wistar | 2 | 2018 | 309 | 0.080 |
Why?
|
| Diet Surveys | 3 | 2011 | 101 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2011 | 79 | 0.080 |
Why?
|
| Empirical Research | 2 | 2014 | 10 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 115 | 0.080 |
Why?
|
| Cats | 1 | 2010 | 121 | 0.080 |
Why?
|
| Pan troglodytes | 1 | 2010 | 74 | 0.080 |
Why?
|
| Piperazines | 2 | 2005 | 272 | 0.080 |
Why?
|
| Preventive Health Services | 1 | 2011 | 58 | 0.080 |
Why?
|
| Bibliometrics | 1 | 2010 | 39 | 0.080 |
Why?
|
| Survival Rate | 4 | 2016 | 2151 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2011 | 119 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2014 | 901 | 0.080 |
Why?
|
| Immunity, Cellular | 2 | 2014 | 200 | 0.080 |
Why?
|
| Food Additives | 1 | 2010 | 5 | 0.080 |
Why?
|
| Epidemics | 1 | 2010 | 58 | 0.080 |
Why?
|
| Antimetabolites | 1 | 2010 | 28 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2011 | 144 | 0.080 |
Why?
|
| Vacuoles | 1 | 2009 | 29 | 0.080 |
Why?
|
| Primates | 1 | 2010 | 82 | 0.080 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 1617 | 0.080 |
Why?
|
| Metabolic Diseases | 2 | 2011 | 137 | 0.080 |
Why?
|
| Dogs | 1 | 2010 | 630 | 0.080 |
Why?
|
| Patient Selection | 1 | 2013 | 726 | 0.080 |
Why?
|
| Drug Industry | 1 | 2009 | 48 | 0.080 |
Why?
|
| Nutritional Requirements | 3 | 2018 | 160 | 0.070 |
Why?
|
| Quetiapine Fumarate | 2 | 2007 | 15 | 0.070 |
Why?
|
| Dibenzothiazepines | 2 | 2007 | 12 | 0.070 |
Why?
|
| Apolipoproteins | 1 | 2009 | 70 | 0.070 |
Why?
|
| AIDS Vaccines | 3 | 2007 | 31 | 0.070 |
Why?
|
| Sequence Deletion | 2 | 2021 | 515 | 0.070 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2008 | 6 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 433 | 0.070 |
Why?
|
| Growth | 1 | 2008 | 92 | 0.070 |
Why?
|
| Sirolimus | 1 | 2010 | 231 | 0.070 |
Why?
|
| Societies, Medical | 3 | 2007 | 794 | 0.070 |
Why?
|
| Dissent and Disputes | 1 | 2008 | 29 | 0.070 |
Why?
|
| Environment, Controlled | 1 | 2008 | 7 | 0.070 |
Why?
|
| Benzodiazepines | 2 | 2007 | 110 | 0.070 |
Why?
|
| Multigene Family | 1 | 2009 | 289 | 0.070 |
Why?
|
| Muscle Cells | 1 | 2007 | 25 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2010 | 404 | 0.070 |
Why?
|
| Yogurt | 1 | 2007 | 13 | 0.070 |
Why?
|
| Mice, Inbred C3H | 3 | 2020 | 108 | 0.070 |
Why?
|
| Chromosomes, Human | 1 | 2008 | 121 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 117 | 0.070 |
Why?
|
| Patient Safety | 2 | 2023 | 444 | 0.070 |
Why?
|
| Trans Fatty Acids | 1 | 2007 | 13 | 0.070 |
Why?
|
| Massachusetts | 2 | 2015 | 118 | 0.070 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2007 | 36 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2008 | 272 | 0.070 |
Why?
|
| Extracellular Fluid | 1 | 2007 | 12 | 0.070 |
Why?
|
| Evolution, Molecular | 1 | 2010 | 657 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2011 | 278 | 0.070 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2007 | 32 | 0.070 |
Why?
|
| Women's Health | 2 | 1998 | 143 | 0.070 |
Why?
|
| United Kingdom | 1 | 2008 | 254 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2010 | 566 | 0.070 |
Why?
|
| Viral Load | 4 | 2018 | 406 | 0.060 |
Why?
|
| Health Status | 2 | 2001 | 387 | 0.060 |
Why?
|
| Virus Integration | 1 | 2007 | 38 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 152 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2009 | 418 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1625 | 0.060 |
Why?
|
| Myocardium | 2 | 2009 | 874 | 0.060 |
Why?
|
| Bison | 1 | 2006 | 1 | 0.060 |
Why?
|
| Informed Consent | 1 | 2009 | 343 | 0.060 |
Why?
|
| Endocrine System | 1 | 2006 | 18 | 0.060 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2007 | 125 | 0.060 |
Why?
|
| Thymidylate Synthase | 1 | 2006 | 20 | 0.060 |
Why?
|
| Biometry | 2 | 2006 | 102 | 0.060 |
Why?
|
| Culture | 2 | 2019 | 69 | 0.060 |
Why?
|
| Lunch | 2 | 2018 | 14 | 0.060 |
Why?
|
| Thymus Gland | 2 | 2003 | 102 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2006 | 98 | 0.060 |
Why?
|
| Children's Health Insurance Program | 1 | 2026 | 7 | 0.060 |
Why?
|
| Genes, Plant | 1 | 2006 | 38 | 0.060 |
Why?
|
| Alaska | 2 | 2016 | 10 | 0.060 |
Why?
|
| Peptide YY | 1 | 2005 | 19 | 0.060 |
Why?
|
| Maternal Age | 1 | 2006 | 137 | 0.060 |
Why?
|
| Endopeptidases | 1 | 2006 | 108 | 0.060 |
Why?
|
| Qualitative Research | 1 | 2009 | 706 | 0.060 |
Why?
|
| Military Personnel | 2 | 2021 | 209 | 0.060 |
Why?
|
| Mass Screening | 2 | 2004 | 825 | 0.060 |
Why?
|
| Adipose Tissue, Brown | 2 | 2018 | 86 | 0.060 |
Why?
|
| Microsatellite Repeats | 1 | 2006 | 232 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 222 | 0.060 |
Why?
|
| Plant Proteins | 1 | 2006 | 89 | 0.060 |
Why?
|
| World Health Organization | 2 | 2016 | 115 | 0.060 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2005 | 29 | 0.060 |
Why?
|
| Software Design | 1 | 2005 | 22 | 0.060 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2026 | 105 | 0.060 |
Why?
|
| Zambia | 1 | 2025 | 21 | 0.060 |
Why?
|
| Computer Graphics | 1 | 2005 | 41 | 0.060 |
Why?
|
| Database Management Systems | 1 | 2005 | 27 | 0.060 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2026 | 61 | 0.060 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2013 | 51 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2006 | 226 | 0.060 |
Why?
|
| Selection Bias | 1 | 2005 | 16 | 0.060 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2009 | 464 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2006 | 436 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2016 | 442 | 0.060 |
Why?
|
| CTLA-4 Antigen | 2 | 2019 | 64 | 0.060 |
Why?
|
| Nitriles | 1 | 2026 | 165 | 0.060 |
Why?
|
| Computers | 1 | 2005 | 69 | 0.060 |
Why?
|
| Mental Recall | 1 | 2006 | 142 | 0.060 |
Why?
|
| Ephedra sinica | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cola | 1 | 2004 | 1 | 0.060 |
Why?
|
| Salix | 1 | 2004 | 1 | 0.060 |
Why?
|
| Forecasting | 2 | 2005 | 361 | 0.060 |
Why?
|
| Molecular Probe Techniques | 1 | 2005 | 23 | 0.060 |
Why?
|
| Arabidopsis | 1 | 2006 | 92 | 0.060 |
Why?
|
| Ephedrine | 1 | 2004 | 5 | 0.060 |
Why?
|
| Heart | 1 | 2009 | 675 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 1078 | 0.060 |
Why?
|
| Serum | 1 | 2005 | 45 | 0.060 |
Why?
|
| Adipogenesis | 1 | 2005 | 80 | 0.060 |
Why?
|
| Benzyl Alcohols | 1 | 2004 | 15 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2006 | 251 | 0.060 |
Why?
|
| Mathematics | 1 | 2004 | 72 | 0.050 |
Why?
|
| Melanocytes | 1 | 2024 | 45 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2004 | 639 | 0.050 |
Why?
|
| Calorimetry | 2 | 1995 | 63 | 0.050 |
Why?
|
| Biological Clocks | 1 | 2024 | 28 | 0.050 |
Why?
|
| Logic | 1 | 2004 | 10 | 0.050 |
Why?
|
| Dermis | 1 | 2024 | 28 | 0.050 |
Why?
|
| Adenovirus Infections, Human | 1 | 2005 | 60 | 0.050 |
Why?
|
| Neurodegenerative Diseases | 1 | 2008 | 288 | 0.050 |
Why?
|
| Neurons | 1 | 2014 | 1990 | 0.050 |
Why?
|
| Risk Reduction Behavior | 2 | 2021 | 148 | 0.050 |
Why?
|
| Epidermis | 1 | 2024 | 64 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2016 | 1316 | 0.050 |
Why?
|
| Thioctic Acid | 1 | 2004 | 9 | 0.050 |
Why?
|
| Tobacco Use Disorder | 1 | 2005 | 90 | 0.050 |
Why?
|
| Safety | 2 | 2005 | 215 | 0.050 |
Why?
|
| Ubiquinone | 1 | 2004 | 27 | 0.050 |
Why?
|
| Spatial Navigation | 1 | 2024 | 20 | 0.050 |
Why?
|
| Government | 1 | 2024 | 13 | 0.050 |
Why?
|
| Lipase | 1 | 2004 | 88 | 0.050 |
Why?
|
| Actigraphy | 1 | 2024 | 53 | 0.050 |
Why?
|
| Workplace | 1 | 2025 | 81 | 0.050 |
Why?
|
| User-Computer Interface | 1 | 2005 | 161 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2006 | 582 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 1236 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2025 | 810 | 0.050 |
Why?
|
| Intention to Treat Analysis | 2 | 2015 | 61 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2024 | 195 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 240 | 0.050 |
Why?
|
| NFATC Transcription Factors | 1 | 2024 | 37 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2004 | 84 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 77 | 0.050 |
Why?
|
| RANK Ligand | 1 | 2024 | 51 | 0.050 |
Why?
|
| Uganda | 1 | 2024 | 94 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2005 | 595 | 0.050 |
Why?
|
| Osteoclasts | 1 | 2024 | 66 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 322 | 0.050 |
Why?
|
| Liver | 3 | 2016 | 1799 | 0.050 |
Why?
|
| Geography | 2 | 2014 | 119 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2024 | 144 | 0.050 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2003 | 32 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 358 | 0.050 |
Why?
|
| Ergonomics | 1 | 2023 | 24 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2024 | 81 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2024 | 864 | 0.050 |
Why?
|
| Seasons | 1 | 2025 | 333 | 0.050 |
Why?
|
| Soybean Proteins | 1 | 2003 | 17 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2003 | 75 | 0.050 |
Why?
|
| Sickness Impact Profile | 1 | 2003 | 40 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2003 | 93 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2003 | 59 | 0.050 |
Why?
|
| Plethysmography, Impedance | 1 | 2002 | 4 | 0.050 |
Why?
|
| Progestins | 1 | 2023 | 42 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 147 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 3917 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 579 | 0.050 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2022 | 13 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2023 | 134 | 0.050 |
Why?
|
| Videotape Recording | 1 | 2002 | 54 | 0.050 |
Why?
|
| Schizophrenic Psychology | 1 | 2003 | 83 | 0.050 |
Why?
|
| Immunodominant Epitopes | 1 | 2002 | 53 | 0.050 |
Why?
|
| Glioblastoma | 1 | 2006 | 346 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2026 | 443 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2004 | 501 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2023 | 188 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2003 | 126 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 676 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 1021 | 0.050 |
Why?
|
| Genetic Loci | 2 | 2015 | 359 | 0.040 |
Why?
|
| Arm | 1 | 2002 | 74 | 0.040 |
Why?
|
| Long-Term Potentiation | 1 | 2022 | 105 | 0.040 |
Why?
|
| Murine hepatitis virus | 1 | 2021 | 2 | 0.040 |
Why?
|
| Thinness | 1 | 2002 | 71 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2002 | 73 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2026 | 328 | 0.040 |
Why?
|
| Orexins | 2 | 2013 | 8 | 0.040 |
Why?
|
| DNA Primers | 2 | 2015 | 609 | 0.040 |
Why?
|
| Immune System | 1 | 2002 | 98 | 0.040 |
Why?
|
| Quercetin | 1 | 2021 | 10 | 0.040 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2021 | 58 | 0.040 |
Why?
|
| Task Performance and Analysis | 1 | 2021 | 83 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 1217 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2003 | 394 | 0.040 |
Why?
|
| Abdomen | 1 | 2002 | 133 | 0.040 |
Why?
|
| Epidemiologic Factors | 1 | 2001 | 9 | 0.040 |
Why?
|
| Uncoupling Protein 1 | 2 | 2013 | 32 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 643 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2000 | 410 | 0.040 |
Why?
|
| Emotions | 1 | 2024 | 361 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2006 | 749 | 0.040 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2020 | 6 | 0.040 |
Why?
|
| Gene Products, tat | 1 | 2000 | 27 | 0.040 |
Why?
|
| Introns | 1 | 2001 | 287 | 0.040 |
Why?
|
| Mice, Inbred DBA | 3 | 2006 | 55 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2021 | 82 | 0.040 |
Why?
|
| Neuropeptides | 2 | 2013 | 111 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 3615 | 0.040 |
Why?
|
| Social Behavior | 1 | 2002 | 217 | 0.040 |
Why?
|
| Receptors, Neuropeptide Y | 2 | 2013 | 8 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 2000 | 58 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2020 | 104 | 0.040 |
Why?
|
| Checklist | 1 | 2020 | 100 | 0.040 |
Why?
|
| Autophagy | 2 | 2016 | 424 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2004 | 1397 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2021 | 339 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2015 | 709 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 301 | 0.040 |
Why?
|
| Hypothalamus | 2 | 2013 | 205 | 0.040 |
Why?
|
| Ion Channels | 2 | 2013 | 206 | 0.040 |
Why?
|
| Accelerometry | 1 | 2019 | 66 | 0.040 |
Why?
|
| Michigan | 1 | 1999 | 47 | 0.040 |
Why?
|
| Markov Chains | 2 | 2011 | 100 | 0.040 |
Why?
|
| Mitochondrial Proteins | 2 | 2013 | 276 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 111 | 0.040 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2020 | 171 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2019 | 201 | 0.040 |
Why?
|
| Isoleucine | 1 | 1999 | 25 | 0.040 |
Why?
|
| Education, Professional | 1 | 2019 | 10 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1999 | 70 | 0.040 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 1999 | 28 | 0.040 |
Why?
|
| Threonine | 1 | 1999 | 62 | 0.040 |
Why?
|
| Exons | 1 | 2001 | 769 | 0.040 |
Why?
|
| Peer Review | 1 | 2019 | 36 | 0.040 |
Why?
|
| Policy | 1 | 2019 | 35 | 0.040 |
Why?
|
| Arctic Regions | 1 | 2018 | 5 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2018 | 20 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2019 | 119 | 0.040 |
Why?
|
| Citrates | 1 | 1998 | 26 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 837 | 0.040 |
Why?
|
| Hyperalgesia | 1 | 2018 | 27 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2018 | 73 | 0.040 |
Why?
|
| Valine | 1 | 1999 | 110 | 0.040 |
Why?
|
| Methionine | 1 | 1999 | 96 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 543 | 0.040 |
Why?
|
| Architecture | 1 | 2018 | 2 | 0.040 |
Why?
|
| Apoptosis | 2 | 2021 | 1861 | 0.040 |
Why?
|
| Corticosterone | 1 | 2018 | 53 | 0.040 |
Why?
|
| Base Sequence | 2 | 2015 | 2782 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2007 | 496 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2013 | 588 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2018 | 235 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2018 | 95 | 0.030 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 86 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 786 | 0.030 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 11 | 0.030 |
Why?
|
| Prader-Willi Syndrome | 1 | 1998 | 62 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 239 | 0.030 |
Why?
|
| Societies, Scientific | 2 | 2007 | 24 | 0.030 |
Why?
|
| Taste Perception | 1 | 2017 | 4 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2016 | 42 | 0.030 |
Why?
|
| Receptors, Serotonin, 5-HT2 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Life Cycle Stages | 1 | 2016 | 25 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Amino Acid Transport Systems | 1 | 2016 | 10 | 0.030 |
Why?
|
| Social Environment | 1 | 1997 | 122 | 0.030 |
Why?
|
| Europe | 2 | 2011 | 372 | 0.030 |
Why?
|
| Daphnia | 1 | 2016 | 3 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2016 | 31 | 0.030 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2016 | 32 | 0.030 |
Why?
|
| Hydrogen Sulfide | 1 | 2016 | 12 | 0.030 |
Why?
|
| Dwarfism | 1 | 2017 | 108 | 0.030 |
Why?
|
| Urban Renewal | 1 | 2016 | 1 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2605 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1947 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 1997 | 235 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 88 | 0.030 |
Why?
|
| Africa | 2 | 2011 | 141 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 136 | 0.030 |
Why?
|
| Body Weight Maintenance | 1 | 2015 | 4 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2015 | 20 | 0.030 |
Why?
|
| Protein Carbonylation | 1 | 2015 | 6 | 0.030 |
Why?
|
| Denmark | 1 | 2015 | 29 | 0.030 |
Why?
|
| Viral Vaccines | 1 | 2019 | 317 | 0.030 |
Why?
|
| HLA-B27 Antigen | 1 | 2015 | 5 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2015 | 48 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2016 | 48 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2016 | 133 | 0.030 |
Why?
|
| Spatial Learning | 1 | 2015 | 15 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 160 | 0.030 |
Why?
|
| Thyroxine | 1 | 1995 | 62 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 2363 | 0.030 |
Why?
|
| Dentate Gyrus | 1 | 2015 | 39 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 242 | 0.030 |
Why?
|
| Sodium Chloride, Dietary | 1 | 1995 | 29 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2015 | 68 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 179 | 0.030 |
Why?
|
| Data Accuracy | 1 | 2014 | 31 | 0.030 |
Why?
|
| Cholelithiasis | 1 | 1994 | 16 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 56 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2018 | 517 | 0.030 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2014 | 20 | 0.030 |
Why?
|
| Glutathione | 1 | 2015 | 198 | 0.030 |
Why?
|
| Running | 1 | 1994 | 32 | 0.030 |
Why?
|
| Human Body | 1 | 1993 | 2 | 0.030 |
Why?
|
| Methylene Blue | 1 | 2013 | 17 | 0.030 |
Why?
|
| RNA, Viral | 2 | 2008 | 513 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling 3 Protein | 1 | 2013 | 11 | 0.030 |
Why?
|
| Microglia | 1 | 2015 | 138 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1995 | 570 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 25 | 0.030 |
Why?
|
| Receptors, Glucagon | 1 | 2013 | 32 | 0.030 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2013 | 47 | 0.030 |
Why?
|
| Carbazoles | 1 | 2013 | 30 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 1995 | 111 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1565 | 0.020 |
Why?
|
| Food Services | 1 | 2013 | 40 | 0.020 |
Why?
|
| Agouti-Related Protein | 1 | 2013 | 48 | 0.020 |
Why?
|
| Morpholines | 1 | 2013 | 68 | 0.020 |
Why?
|
| Psychometrics | 1 | 1997 | 671 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2007 | 400 | 0.020 |
Why?
|
| Monkey Diseases | 1 | 2012 | 17 | 0.020 |
Why?
|
| Finite Element Analysis | 1 | 2012 | 35 | 0.020 |
Why?
|
| Philadelphia | 1 | 2012 | 29 | 0.020 |
Why?
|
| Mutation | 2 | 2024 | 6177 | 0.020 |
Why?
|
| Metabolomics | 1 | 2016 | 493 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 792 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 714 | 0.020 |
Why?
|
| Self Care | 1 | 2014 | 231 | 0.020 |
Why?
|
| Uncertainty | 1 | 2012 | 96 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2011 | 45 | 0.020 |
Why?
|
| Cell Division | 2 | 2004 | 730 | 0.020 |
Why?
|
| Radius | 1 | 2011 | 37 | 0.020 |
Why?
|
| RNA | 2 | 2006 | 531 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2012 | 265 | 0.020 |
Why?
|
| Time | 1 | 2011 | 96 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2011 | 208 | 0.020 |
Why?
|
| Middle East | 1 | 2011 | 37 | 0.020 |
Why?
|
| Americas | 1 | 2011 | 52 | 0.020 |
Why?
|
| Prognosis | 1 | 2021 | 4952 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 233 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2019 | 3864 | 0.020 |
Why?
|
| Asia | 1 | 2011 | 125 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1995 | 481 | 0.020 |
Why?
|
| Syndrome | 1 | 1993 | 1166 | 0.020 |
Why?
|
| Age of Onset | 1 | 2012 | 632 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8588 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 1989 | 0.020 |
Why?
|
| Drosophila Proteins | 1 | 2016 | 788 | 0.020 |
Why?
|
| Leukocytes | 1 | 2011 | 211 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2011 | 230 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 2009 | 16 | 0.020 |
Why?
|
| Glycogen | 1 | 2009 | 50 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 2009 | 46 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2007 | 2971 | 0.020 |
Why?
|
| Fetal Death | 1 | 2010 | 119 | 0.020 |
Why?
|
| Ovulation | 1 | 2010 | 106 | 0.020 |
Why?
|
| Apolipoprotein A-V | 1 | 2009 | 23 | 0.020 |
Why?
|
| Uncoupling Protein 3 | 1 | 2008 | 7 | 0.020 |
Why?
|
| Breeding | 1 | 2008 | 19 | 0.020 |
Why?
|
| Apolipoproteins A | 1 | 2009 | 53 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 228 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 2009 | 46 | 0.020 |
Why?
|
| Atrophy | 1 | 2009 | 251 | 0.020 |
Why?
|
| CD36 Antigens | 1 | 2008 | 35 | 0.020 |
Why?
|
| Vaccines, Attenuated | 1 | 2008 | 174 | 0.020 |
Why?
|
| Thymectomy | 1 | 2008 | 24 | 0.020 |
Why?
|
| Registries | 1 | 1995 | 1599 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 366 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 1018 | 0.020 |
Why?
|
| Organ Size | 1 | 2008 | 435 | 0.020 |
Why?
|
| Body Surface Area | 1 | 2007 | 37 | 0.020 |
Why?
|
| Glucose Clamp Technique | 1 | 2007 | 75 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2007 | 33 | 0.020 |
Why?
|
| Transcriptome | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Benchmarking | 1 | 2007 | 138 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2006 | 43 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2006 | 67 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 172 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 193 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2006 | 228 | 0.010 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2005 | 23 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2006 | 152 | 0.010 |
Why?
|
| Transgenes | 1 | 2006 | 323 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 199 | 0.010 |
Why?
|
| Inbreeding | 1 | 2005 | 7 | 0.010 |
Why?
|
| Sequence Analysis, RNA | 1 | 2008 | 420 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2005 | 29 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 53 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 741 | 0.010 |
Why?
|
| Texas | 1 | 2014 | 3615 | 0.010 |
Why?
|
| Equipment Design | 1 | 2007 | 555 | 0.010 |
Why?
|
| Sigmoidoscopy | 1 | 2004 | 11 | 0.010 |
Why?
|
| Immunization | 1 | 2006 | 307 | 0.010 |
Why?
|
| Occult Blood | 1 | 2004 | 33 | 0.010 |
Why?
|
| Coenzymes | 1 | 2004 | 12 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 329 | 0.010 |
Why?
|
| Free Radicals | 1 | 2004 | 35 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2004 | 55 | 0.010 |
Why?
|
| Chromosomes | 1 | 2004 | 117 | 0.010 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2004 | 23 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 2004 | 58 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 910 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 2004 | 27 | 0.010 |
Why?
|
| Adiponectin | 1 | 2004 | 124 | 0.010 |
Why?
|
| Peptide Hormones | 1 | 2004 | 71 | 0.010 |
Why?
|
| Cytosol | 1 | 2004 | 140 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2004 | 96 | 0.010 |
Why?
|
| Disease Management | 1 | 2007 | 564 | 0.010 |
Why?
|
| Chromosomes, Mammalian | 1 | 2003 | 41 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 2003 | 13 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 199 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2005 | 262 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 148 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 2003 | 12 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 293 | 0.010 |
Why?
|
| Callitrichinae | 1 | 2002 | 1 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2004 | 231 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2005 | 158 | 0.010 |
Why?
|
| C-Peptide | 1 | 2003 | 107 | 0.010 |
Why?
|
| DNA | 1 | 2008 | 1442 | 0.010 |
Why?
|
| Wakefulness | 1 | 2003 | 103 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 2002 | 50 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2002 | 45 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2003 | 366 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 665 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1488 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2005 | 781 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2004 | 449 | 0.010 |
Why?
|
| Viscera | 1 | 2001 | 55 | 0.010 |
Why?
|
| Electron Transport | 1 | 2001 | 60 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 223 | 0.010 |
Why?
|
| Oxygen | 1 | 2004 | 552 | 0.010 |
Why?
|
| Reference Standards | 1 | 2001 | 231 | 0.010 |
Why?
|
| Oxidative Phosphorylation | 1 | 2001 | 130 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1571 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2001 | 659 | 0.010 |
Why?
|
| Self Disclosure | 1 | 1998 | 28 | 0.010 |
Why?
|
| Electric Impedance | 1 | 1999 | 72 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 1999 | 86 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2007 | 1957 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2005 | 1099 | 0.010 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 123 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2001 | 832 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2004 | 775 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2000 | 2564 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1996 | 171 | 0.010 |
Why?
|
| Spinal Diseases | 1 | 1995 | 47 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1994 | 97 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1994 | 79 | 0.010 |
Why?
|
| Body Fluids | 1 | 1994 | 46 | 0.010 |
Why?
|
| Muscles | 1 | 1994 | 222 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1994 | 156 | 0.010 |
Why?
|
| Bilirubin | 1 | 1994 | 126 | 0.010 |
Why?
|
| Potassium | 1 | 1994 | 270 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 1788 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1994 | 974 | 0.000 |
Why?
|